Reducing reliance on chemical pesticides through the transfer of development and sales rights for plant vaccines
First written in FY2021. 6 of 9 entries say "Advanced", first in FY2022-Q1. Latest entry: 2026-06-15.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「We will steadily advance preparations for the launch of new plant vaccines, a key factor in expanding our business foundation.」
The company explicitly stated its policy of moving from continued research and development of plant vaccines to the launch of new products. - FY2023AdvancedAnnual report
「ベルグ福島株式会社 has established a system for producing all existing plant vaccines in-house and will continue to focus on developing new plant vaccines, while pursuing a system for supplying safe and reliable vegetable seedlings that control viral diseases without relying on chemical pesticides.」
The company moved to a system for producing all existing plant vaccines in-house and continues to pursue the development of new vaccines and a supply system for seedlings without relying on chemical pesticides. - FY2022RestatedAnnual report
「At ベルグ福島株式会社, research and development of plant vaccines began following the launch of the Plant Vaccine Comprehensive Research Institute, completed in February 2022. Plant vaccines are expected to provide effective disease-control measures without relying on chemical pesticides, as well as environmentally responsible production, stable production and improved quality. We aim to establish a system for supplying safe and reliable vegetable seedlings to producers nationwide.」
The company continued to pursue research and development at the Plant Vaccine Comprehensive Research Institute and a nationwide supply system for safe and reliable seedlings without relying on chemical pesticides throughout the fiscal year. - FY2022-Q3RestatedAnnual report
「At ベルグ福島株式会社, research and development of plant vaccines began following the launch of the Plant Vaccine Comprehensive Research Institute. By developing high-value-added products using plant vaccines, we aim to strengthen competitiveness and improve earnings power, and to establish a system for supplying vegetable seedlings nationwide that provide safe and reliable control of viral diseases without relying on chemical pesticides.」
The company continues to pursue research and development at the Plant Vaccine Comprehensive Research Institute and a nationwide supply system for safe and reliable seedlings without relying on chemical pesticides. - FY2022-Q2AdvancedAnnual report
「At ベルグ福島, the Plant Vaccine Comprehensive Research Institute was completed and research and development of plant vaccines began. By developing high-value-added products using plant vaccines, we aim to strengthen competitiveness and improve earnings power, and to establish a system for supplying vegetable seedlings nationwide that provide safe and reliable control of viral diseases without relying on chemical pesticides.」
The Plant Vaccine Comprehensive Research Institute was completed and research and development began. The company moved to the stage of pursuing the commercialization and nationwide supply of vaccinated seedlings without relying on chemical pesticides. - FY2022-Q1AdvancedAnnual report
「We also began selling plant-vaccine formulations in January 2022 and will strengthen domestic promotion activities together with vaccinated seedlings.」
Sales of plant-vaccine formulations began in January 2022, advancing domestic promotion activities combining the formulations with vaccinated seedlings. In addition, following the acquisition of additional shares in ベルグ福島 in February 2022, the company indicated a policy of pursuing the early commercialization of plant-vaccine development at the company and strengthening sales in the Tohoku region. - FY2021First statedAnnual report
「Beginning in the fiscal year ending October 2022, we decided to launch full-scale development of plant vaccines at consolidated subsidiary ベルグ福島株式会社. …As sales rights changed from the company to us in January 2022 and we became the sole distributor of the plant-vaccine formulations, we will strengthen domestic promotion activities together with vaccinated seedlings.」
The company began full-scale plant-vaccine development at ベルグ福島 in the fiscal year ending October 2022 and, after acquiring the formulation sales rights in January 2022, planned to strengthen domestic distribution together with vaccinated seedlings. This was identified as a standalone theme for the first time.